89 active trials 44 recruiting 8 Phase 3 64 sponsors 12 changes in 30 days
| Early Phase 1 | 1 | |
| Phase 1 | 8 | |
| Phase 1/2 | 1 | |
| Phase 2 | 25 | |
| Phase 2/3 | 1 | |
| Phase 3 | 7 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07284602 | Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to… | PureTech | Recruiting | 2026-08-27 |
| NCT07671911 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine… | Trevi Therapeutics | Recruiting | 2026-07-10 |
| NCT07082842 | Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | Sunshine Lake Pharma Co., Ltd. | Recruiting | 2026-04-21 |
| NCT07464912 | A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension… | Beijing Tide Pharmaceutical Co., Ltd | Recruiting | 2026-03-11 |
| NCT07719023 | A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary… | Shanghai Ark Biopharmaceutical Co., Ltd. | Not Yet Recruiting | 2026-07-22 |
| NCT07687459 | Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic… | InSilico Medicine Hong Kong Limited | Not Yet Recruiting | 2026-07-07 |
| NCT07519070 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate… | Haisco Pharmaceutical Group Co., Ltd. | Not Yet Recruiting | 2026-04-09 |
| Phase 2/3 | ||||
| NCT06125327 | SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis… | Guangzhou JOYO Pharma Co., Ltd | Recruiting | 2024-11-19 |
| Phase 2 | ||||
| NCT06968845 | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Rein Therapeutics | Recruiting | 2026-08-13 |
| NCT06967805 | WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Mediar Therapeutics | Recruiting | 2026-08-10 |
| NCT07194382 | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02… | Avalyn Pharma Inc. | Recruiting | 2026-08-10 |
| NCT06951217 | An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | Avalyn Pharma Inc. | Recruiting | 2026-08-07 |
| NCT07036523 | A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With… | Boehringer Ingelheim | Recruiting | 2026-07-28 |
| NCT07679893 | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With… | Mannkind Corporation | Recruiting | 2026-07-24 |
| NCT07652658 | A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. | AstraZeneca | Recruiting | 2026-06-25 |
| NCT07447102 | Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis | Dragonboat Biopharmaceutical Company Limited | Recruiting | 2026-05-13 |
| NCT05571059 | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Cumberland Pharmaceuticals | Recruiting | 2026-03-05 |
| NCT07121413 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and… | Shanghai Synvida Biotechnology Co.,Ltd. | Recruiting | 2026-02-11 |
| NCT07192939 | Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the… | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | 2025-12-24 |
| NCT06747923 | SB17170 Phase 2 Trial in IPF Patients | SPARK Biopharma | Recruiting | 2025-11-19 |
| NCT05975983 | Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary… | InSilico Medicine Hong Kong Limited | Recruiting | 2025-11-12 |
| NCT06588686 | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic… | Vicore Pharma AB | Active, Not Recruiting | 2026-08-17 |
| NCT07728721 | Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary… | Haisco Pharmaceutical Group Co., Ltd. | Not Yet Recruiting | 2026-07-27 |
| NCT05389215 | Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | Daewoong Pharmaceutical Co. LTD. | Active, Not Recruiting | 2026-07-16 |
| NCT05828953 | Anlotinib Capsules in the Treatment for IPF/PF-ILDs | First Affiliated Hospital of Wenzhou Medical University | Active, Not Recruiting | 2026-06-05 |
University of Pittsburgh (4) · Haisco Pharmaceutical Group Co., Ltd. (3) · Henan University of Traditional Chinese Medicine (3) · Hospital de Granollers (3) · Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (3) · Istituto Clinico Humanitas (3) · Assiut University (2) · Avalyn Pharma Inc. (2) · Boehringer Ingelheim (2) · First Affiliated Hospital of Wenzhou Medical University (2)